18 completed, 4 unknown, 3 terminated, 3 withdrawn. 31 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 18, Unknown 4, Terminated 3, Withdrawn 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 4 | Withdrawn 2, Completed 1, Unknown 1 |
Follow Inhalation: new trials by email Literature Review of Inhalation trials Research Report on Inhalation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment Aprotinin (inhaled), Placebo (Sodium Chloride) - Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Recruiting | Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion | 156 | 2026-06-18 | 2026-07-15 |
| Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease TQC3721 Suspension for Inhalation - Chronic Obstructive Pulmonary Disease | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 800 | 2026-04-14 | 2026-09-28 |
| Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease TQC3721 Suspension for inhalation, Placebo of TQC3721 Suspension for Inhalation - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 666 | 2025-09-01 | 2025-09-10 |
| A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD HL231 Solution for Inhalation, Ultibro 110μg/50 μg - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 487 | 2023-12-11 | 2026-04-06 |
| Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 FB2001, FB2001 placebo - Mild to Moderate COVID-19 | Phase 2 / Phase 3 | Unknown | Frontier Biotechnologies Inc. | 1336 | 2023-01-04 | 2023-01-09 |
| A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis OligoG Dry powder for inhalation - Cystic Fibrosis | Phase 2 / Phase 3 | Withdrawn | AlgiPharma AS | 2021-09-01 | 2022-06-30 | |
| Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women Nitrous oxide gas for inhalation, Oxygen Gas for Inhalation - Contraceptive Devices, Long-Acting Reversible Contraception | Phase 2 / Phase 3 | Withdrawn | Boston Children's Hospital | 2021-06-01 | 2022-09-16 | |
| Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" Alpha 1-Antitrypsin, Placebo - Alpha 1-Antitrypsin Deficiency | Phase 3 | Terminated | Kamada, Ltd. | 98 | 2019-11-25 | 2026-08-12 |
| Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure Yiqi Huoxue Huatan granule, Placebo Yiqi Huoxue Huatan granule - Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure | Phase 3 | Unknown | Peking University People's Hospital | 372 | 2019-10-08 | 2020-01-07 |
| Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD Bufei Yishen granule, Placebo Bufei Yishen granule, Tiotropium Bromide Powder for Inhalation - Chronic Obstructive Pulmonary Disease | Phase 3 | Unknown | Henan University of Traditional Chinese Medicine | 348 | 2019-06-01 | 2019-06-06 |
| Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. CMAB007, Symbicort, Seretide - Asthma, Allergic | Phase 3 | Completed | Shanghai Biomabs Pharmaceutical Co., Ltd. | 393 | 2018-05-09 | 2021-10-11 |
| Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease Acupuncture, Conventional drug, Acupuncture plus conventional drug - Pulmonary Disease, Chronic Obstructive | Phase 3 | Unknown | Henan University of Traditional Chinese Medicine | 150 | 2017-05-01 | 2017-05-30 |
| AMPLIFY - D6571C00001 Duaklir USA Phase III Study Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg) - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 1595 | 2016-07-05 | 2018-11-09 |
| Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone LAI (Liposomal Amikacin for Inhalation) 590 mg - Mycobacterium Infections, Nontuberculous | Phase 3 | Completed | Insmed Incorporated | 336 | 2015-05-27 | 2020-05-07 |
| Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3 Terbutaline sulphate, Placebo for terbutaline sulphate - Asthma | Phase 3 | Completed | AstraZeneca | 95 | 2015-03-01 | 2017-01-13 |
| OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis azithromycin, placebo, Tobramycin solution for inhalation - Cystic Fibrosis | Phase 3 | Completed | Bonnie Ramsey | 221 | 2014-06-01 | 2019-10-01 |
| Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4) Ciprofloxacin dispersion for inhalation, Placebo - Non Cystic Fibrosis Bronchiectasis | Phase 3 | Completed | Aradigm Corporation | 304 | 2014-05-28 | 2021-03-26 |
| Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo - Bronchiectasis | Phase 3 | Completed | Bayer | 521 | 2014-04-30 | 2017-10-02 |
| Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3) Ciprofloxacin dispersion for inhalation, Placebo - Non Cystic Fibrosis Bronchiectasis | Phase 3 | Completed | Aradigm Corporation | 278 | 2014-03-31 | 2021-03-26 |
| Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection Liposomal amikacin for inhalation - Cystic Fibrosis | Phase 3 | Completed | Insmed Incorporated | 206 | 2012-10-05 | 2020-06-17 |
Showing 20 of 31. Sign in to see all of them.
Cystic Fibrosis (8) · Pulmonary Disease, Chronic Obstructive (7) · Respiratory Tract Infections (4) · Pseudomonas Infections (3) · Asthma (2) · Bronchiectasis (2) · Respiratory Aspiration (2) · alpha 1-Antitrypsin Deficiency (2) · Acute Lung Injury (1) · Agnosia (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchiolitis, Viral (1) · Cardiomyopathies (1)
Insmed Incorporated (4) · Aradigm Corporation (2) · AstraZeneca (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Henan University of Traditional Chinese Medicine (2) · Kamada, Ltd. (2) · Mallinckrodt (2) · AlgiPharma AS (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Bayer (1) · Bonnie Ramsey (1) · Boston Children's Hospital (1) · Frontier Biotechnologies Inc. (1) · Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion (1)
Germany (10) · United Kingdom (10) · United States (10) · China (9) · Netherlands (8) · Spain (8) · Canada (7) · France (7) · Hungary (6) · Ireland (6) · Poland (6) · Israel (5) · Italy (5) · Australia (4) · Bulgaria (4)
Gina Eagle, MD (4) · Bonnie Ramsey, MD (1) · Cheng Yao (1) · Claus Neurohr, MD (1) · Felix Ratjen (1) · Jan Stolk, Prof (1) · Jan Stolk, Professor (1) · Jiansheng Li, Professor (1) · Leif Bjermer, MD, Professor (1) · Michael Konstan, MD (1)
PMID 30658914, PMID 32554534, PMID 19996339, PMID 20405117, PMID 26935334, PMID 28232118, PMID 28495619, PMID 28586918, PMID 29371384, PMID 29890086, PMID 30216086, PMID 30962681, PMID 31451351, PMID 31467115, PMID 33595792, PMID 33887244, PMID 34144923, PMID 37665565, PMID 37955027, PMID 38277865, PMID 39956529, PMID 40609812, PMID 41186908, PMID 41345745
2004 (1), 2014 (1), 2018 (1), 2025 (1), U01HL114589 (1), U01HL114623 (1)